Phase II study of cabazitaxel as 2nd-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes.
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 10 May 2017 Planned End Date changed from 1 Mar 2017 to 1 May 2019.